Healthcare

Starpharma Holdings Limited(ASX:SPL)has received a USD 5.5 million (AUD 8.5 million) upfront payment from Genentech, a member of the Roche Group. Under the partnership, Starpharma will apply its proprietary DEP® (dendrimer enhanced product) technology to develop dendrimer-drug conjugates that combine Genentech’s compounds with selected …

Orthocell Limited (ASX:OCC) has secured firm commitments to raise USD 30 million before costs through an institutional placement. The new shares are priced at USD 1.30 each, representing a 9.1% discount to the last traded price of USD 1.43. The placement attracted broad interest …

TrivarX (ASX:TRI) has entered into a binding intellectual property option agreement to acquire the Stabl-Im™ metastatic brain technology from Nucleics Pty Ltd. This acquisition includes 100% ownership of the Stabl-Im IP and related stable isotope cancer diagnostic IP. Stabl-Im technology enables safe, non-invasive imaging …

The S&P/ASX 200 Health Care (XHJ) sector tracks Australia’s listed healthcare companies and serves as a key industry benchmark. As of 15 October 2025, the index (XHJ) rose 2.07% to 39,154.80 points from its last close of 38,360.60. Three ASX-listed healthcare companies record notable …

Orthocell Limited (ASX:OCC) develops regenerative products for bone, soft tissue, and nerve repair. Key products include Striate+™ for dental applications and Remplir™ for nerve reconstruction.

Neurizon Therapeutics Limited (ASX:NUZ) has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001. The removal of this hold allows Neurizon to advance NUZ-001 into the Phase 2/3 HEALEY ALS Platform Trial, anticipated …

Race Oncology Ltd (ASX:RAC) saw its shares jump more than 48% in afternoon trading on Thursday, at AUD 4.61, after the company announced a significant breakthrough in its cancer research. The company revealed that it had identified the primary mechanism of action of its …